Clinical Trials Logo

Relapsed Hematologic Malignancy clinical trials

View clinical trials related to Relapsed Hematologic Malignancy.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05205252 Withdrawn - Clinical trials for Relapsed Hematologic Malignancy

A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.

ARIA
Start date: December 22, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This trial will study how safely the tazemetostat works with other therapies in various hematological malignancies. Hematologic malignancies are cancers that most often begin in the bone marrow or lymph nodes where blood precursors are produced. They are often called blood cancers and fall into three categories: leukemia, lymphoma and myeloma. Tazemetostat has been found to be a safe and effective drug that works in patients with follicular lymphoma where the disease has come back after treatment (known as relapsed) and when other treatment no longer works (known as refractory). Combining tazemetostat with other treatments may work better in treating patients with hematological malignancies and may improve disease response and durability of response.